top of page
Browse by category
Search
Studies investigate GLP-1s promise in treating substance use disorders
There have been reports that glucagon-like peptide-1 receptor agonists (GLP-1RAs) may also have the potential to treat alcohol and drug...
GLP-1 agonists may affect the interpretation of oncological FDG PET-CT scans
The growing use of GLP-1 receptor agonists may affect the interpretation of oncological FDG PET-CT scans, according to research presented at the 38th Annual Congress of the European Association of Nuclear Medicine (EANM'25). GLP-1 receptor agonists are now widely prescribed for individuals with type 2 diabetes and weight loss, with a 700% increase in usage reported in the US between 2019 and 2023. These medications alter glucose metabolism, gastric motility and sympathetic to
High cost or insurance-related issues are the most common reasons for discontinuation with semaglutide or tirzepatide
High cost or insurance-related issues are the most common reasons for treatment discontinuation with semaglutide or tirzepatide for...
Metabolically active visceral fat linked to aggressive endometrial cancer
High metabolic activity of visceral fat may be associated with more aggressive endometrial cancer, according to a presentation, ‘Visceral...
Significant increase of weight loss drugs before bariatric surgery
There has been a 16-fold increase in the use of weight loss drugs among patients before metabolic and bariatric surgery, signalling an...
MBS associated with significant reductions in the rates of adverse hepatic and extrahepatic outcomes in patients with steatotic liver disease
In patients with steatotic liver disease (SLD), metabolic bariatric surgery (MBS) is associated with significant reductions in the rates...
Browse by tag
bottom of page